Global Alpha- Antitrypsin Deficiency Treatment Market Growth (Status and Outlook) 2025-2031

Global Alpha- Antitrypsin Deficiency Treatment Market Growth (Status and Outlook) 2025-2031

The global Alpha- Antitrypsin Deficiency Treatment market size is predicted to grow from US$ 2171 million in 2025 to US$ 3709 million in 2031; it is expected to grow at a CAGR of 9.3% from 2025 to 2031.

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Alpha- Antitrypsin Deficiency Treatment Industry Forecast” looks at past sales and reviews total world Alpha- Antitrypsin Deficiency Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Alpha- Antitrypsin Deficiency Treatment sales for 2025 through 2031. With Alpha- Antitrypsin Deficiency Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alpha- Antitrypsin Deficiency Treatment industry.

This Insight Report provides a comprehensive analysis of the global Alpha- Antitrypsin Deficiency Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Alpha- Antitrypsin Deficiency Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Alpha- Antitrypsin Deficiency Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alpha- Antitrypsin Deficiency Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alpha- Antitrypsin Deficiency Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Alpha- Antitrypsin Deficiency Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others

Segmentation by Application:
Clinic
Hospital
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.